Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia.
Adolescent
Biomarkers, Tumor
/ genetics
Bone Marrow
/ chemistry
Child
Child, Preschool
Female
Flow Cytometry
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Humans
Infant
Male
Neoplasm Recurrence, Local
/ genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ genetics
Sequence Analysis, RNA
Single-Cell Analysis
Tumor Microenvironment
Up-Regulation
Young Adult
B cell leukemia
Th1
immune response
regulatory T cell
relapse
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
06
10
2021
received:
04
05
2021
accepted:
25
10
2021
pubmed:
31
10
2021
medline:
13
1
2022
entrez:
30
10
2021
Statut:
ppublish
Résumé
Due to the considerable success of cancer immunotherapy for leukemia, the tumor immune environment has become a focus of intense research; however, there are few reports on the dynamics of the tumor immune environment in leukemia. Here, we analyzed the tumor immune environment in pediatric B cell precursor acute lymphoblastic leukemia by analyzing serial bone marrow samples from nine patients with primary and recurrent disease by mass cytometry using 39 immunophenotype markers, and transcriptome analysis. High-dimensional single-cell mass cytometry analysis elucidated a dynamic shift of T cells from naïve to effector subsets, and clarified that, during relapse, the tumor immune environment comprised a T helper 1-polarized immune profile, together with an increased number of effector regulatory T cells. These results were confirmed in a validation cohort using conventional flow cytometry. Furthermore, RNA transcriptome analysis identified the upregulation of immune-related pathways in B cell precursor acute lymphoblastic leukemia cells during relapse, suggesting interaction with the surrounding environment. In conclusion, a tumor immune environment characterized by a T helper 1-polarized immune profile, with an increased number of effector regulatory T cells, could contribute to the pathophysiology of recurrent B cell precursor acute lymphoblastic leukemia. This information could contribute to the development of effective immunotherapeutic approaches against B cell precursor acute lymphoblastic leukemia relapse.
Identifiants
pubmed: 34716967
doi: 10.1111/cas.15186
pmc: PMC8748249
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-52Subventions
Organisme : AMED
ID : JP21ck0106531
Organisme : Bristol Myers Squibb
Organisme : Mochida Memorial Foundation for Medical and Pharmaceutical Research
Organisme : Mother and Child Health Foundation
Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Hematology. 2015 Oct;20(9):523-9
pubmed: 26119924
Cell Mol Immunol. 2018 Apr;15(4):299-311
pubmed: 29082918
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):565-9
pubmed: 25696912
Immunity. 2012 Nov 16;37(5):785-99
pubmed: 23123060
F1000Res. 2017 May 26;6:748
pubmed: 28663787
Semin Immunopathol. 2012 Jan;34(1):133-49
pubmed: 21971685
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Front Oncol. 2019 May 17;9:415
pubmed: 31165047
Cancer Discov. 2018 Sep;8(9):1066-1068
pubmed: 30181171
Blood. 2010 Dec 2;116(23):4874-84
pubmed: 20699438
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
J Hematol Oncol. 2015 Oct 08;8:111
pubmed: 26449653
J Pediatr Hematol Oncol. 2015 Oct;37(7):498-501
pubmed: 26376233
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Int Immunol. 2016 Apr;28(4):163-71
pubmed: 26874355
Oncogene. 2019 Mar;38(13):2420-2431
pubmed: 30532071
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Cancer Sci. 2020 Jul;111(7):2223-2233
pubmed: 32324315
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
J Exp Med. 2009 Jan 16;206(1):69-78
pubmed: 19139170
Front Immunol. 2016 May 17;7:184
pubmed: 27242791
Oncol Lett. 2012 Feb;3(2):421-424
pubmed: 22740924
Leukemia. 2020 Oct;34(10):2607-2620
pubmed: 32203137
Nat Commun. 2011;2:240
pubmed: 21407206
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Cancer Cell. 2020 Sep 14;38(3):380-399.e13
pubmed: 32649887
Oncol Rep. 2016 May;35(5):2699-706
pubmed: 26985678
Front Immunol. 2019 Feb 27;10:333
pubmed: 30873179
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Commun Biol. 2019 May 14;2:183
pubmed: 31098416
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Int Immunol. 2000 Feb;12(2):151-60
pubmed: 10653850
Leukemia. 2019 Jul;33(7):1570-1582
pubmed: 30635636
Sci Rep. 2018 Jul 17;8(1):10770
pubmed: 30018331
J Pediatr Hematol Oncol. 2013 Oct;35(7):509-13
pubmed: 23887024
J Immunol. 2000 Sep 15;165(6):3136-44
pubmed: 10975827
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Oncotarget. 2016 Nov 22;7(47):76902-76919
pubmed: 27708227
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Immunology. 2014 May;142(1):124-39
pubmed: 24354800
J Clin Invest. 1997 Nov 15;100(10):2552-61
pubmed: 9366570
Curr Opin Immunol. 2014 Apr;27:1-7
pubmed: 24413387
Cancer Sci. 2022 Jan;113(1):41-52
pubmed: 34716967
Immunopharmacol Immunotoxicol. 2018 Apr;40(2):158-167
pubmed: 29388481
Br J Cancer. 2015 Apr 28;112(9):1421-7
pubmed: 25856776
Cytometry A. 2012 Sep;81(9):727-31
pubmed: 22887982
Immunity. 2019 Feb 19;50(2):302-316
pubmed: 30784578
Pediatr Infect Dis J. 2014 Sep;33(9):e219-25
pubmed: 24618935
Biomed Res Int. 2015;2015:386165
pubmed: 26090405
Lancet. 2020 Apr 4;395(10230):1146-1162
pubmed: 32247396
Cytokine. 2015 Feb;71(2):302-11
pubmed: 25497737
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
Cell Syst. 2018 May 23;6(5):612-620.e5
pubmed: 29605184